FY2025 EPS Forecast for Caribou Biosciences Cut by Analyst

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Investment analysts at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for shares of Caribou Biosciences in a research note issued to investors on Monday, May 12th. Cantor Fitzgerald analyst R. Bienkowski now anticipates that the company will post earnings of ($1.85) per share for the year, down from their previous estimate of ($1.31). The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share.

Separately, HC Wainwright reiterated a “buy” rating and set a $3.00 price objective (down previously from $9.00) on shares of Caribou Biosciences in a research report on Monday, April 28th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $9.33.

Caribou Biosciences Stock Down 4.3%

Shares of NASDAQ CRBU opened at $0.78 on Wednesday. The firm has a 50-day simple moving average of $0.88 and a 200-day simple moving average of $1.44. Caribou Biosciences has a 52 week low of $0.66 and a 52 week high of $3.91. The stock has a market capitalization of $72.80 million, a price-to-earnings ratio of -0.47 and a beta of 2.36.

Caribou Biosciences (NASDAQ:CRBU) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.43). Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The firm had revenue of $2.35 million for the quarter, compared to analyst estimates of $1.48 million.

Hedge Funds Weigh In On Caribou Biosciences

A number of hedge funds have recently modified their holdings of CRBU. Aberdeen Group plc lifted its holdings in shares of Caribou Biosciences by 126.5% in the 1st quarter. Aberdeen Group plc now owns 411,144 shares of the company’s stock worth $375,000 after acquiring an additional 229,657 shares during the last quarter. Nuveen LLC acquired a new position in Caribou Biosciences during the 1st quarter worth $302,000. Nelson Capital Management LLC increased its stake in shares of Caribou Biosciences by 31.1% during the first quarter. Nelson Capital Management LLC now owns 85,020 shares of the company’s stock worth $78,000 after buying an additional 20,162 shares during the period. Cerity Partners LLC grew its holdings in Caribou Biosciences by 163.6% during the 1st quarter. Cerity Partners LLC now owns 40,722 shares of the company’s stock worth $37,000 after acquiring an additional 25,271 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. acquired a new position in shares of Caribou Biosciences during the first quarter worth $559,000. 77.51% of the stock is currently owned by hedge funds and other institutional investors.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.